Literature DB >> 27683142

Suicide risk and psychiatric comorbidity in patients with psoriasis.

Maurizio Pompili1, Marco Innamorati2, Sara Trovarelli1, Alessandra Narcisi3, Samantha Bellini1, Diego Orsini3, Alberto Forte1, Denise Erbuto3, Elisabetta Botti3, Dorian A Lamis4, Paolo Girardi1, Antonio Costanzo5.   

Abstract

OBJECTIVES: To examine the occurrence of stressful life events, psychological comorbidity and suicide risk in patients with psoriasis or other dermatological conditions.
METHODS: Consecutive adult outpatients with psoriasis or other dermatological conditions completed a sociodemographic questionnaire and the Hamilton scales for depression and anxiety.
RESULTS: The study included 157 patients (91 with psoriasis; 66 with other conditions [melanoma; allergy]). Patients with psoriasis were significantly more likely to have experienced major life events in the 12 months before diagnosis, have had a psychiatric diagnosis and to have experienced past suicidal ideation than patients with other dermatological conditions.
CONCLUSIONS: Patients with psoriasis have an increased risk of psychiatric comorbidities, suicidal ideation, and long-term course of the disease compared with patients who have other dermatological conditions. Psychiatric assessment is highly recommended in patients with psoriasis.
© The Author(s) 2016.

Entities:  

Keywords:  Anxiety; depression; dermatological diseases; health-related quality-of-life; psoriasis; stress; suicidal ideation

Year:  2016        PMID: 27683142      PMCID: PMC5536523          DOI: 10.1177/0300060515593253

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


Introduction

Psoriasis is a common condition, affecting up to 3% of the population in industrialized countries.[1,2] Although its aetiology is not entirely clear, psoriasis appears to be a multifactorial inflammatory mediated disease, involving both genetic and environmental causes.[3,4] In addition, emotional stress seems to plays an important role in the onset and exacerbation of psoriasis.[5-7] As with other dermatological conditions, psoriasis worsens with stress in between 37% and 78% of patients,[7,8] and stressful life events are both a cause and an aggravating factor for psoriasis.[5,7] In over 40% of cases, the onset of psoriasis occurs in patients <30 years of age,[9] which may have a serious negative psychosocial impact for individuals, including feelings of stigmatization and increased risk of depression and/or anxiety.[10,11] Some studies have demonstrated that >90% of patients with psoriasis have a psychiatric diagnosis, mostly related to depression and anxiety disorders.[12,13] Evidence suggests a relationship between psoriasis and an increased risk of suicidality,[14-16] with psoriasis having a stronger association with risk of suicidal ideation than other dermatological conditions.[17] The aim of the current study was to examine the occurrence of stressful life events, psychological comorbidity and suicide risk in patients with psoriasis.

Patients and methods

Study population

The study enrolled consecutive adult outpatients with dermatological conditions who attended the Department of Dermatology, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy between October 2013 and September 2014. Inclusion criteria were: at least one dermatological disease; aged 18–65 years; ability to provide informed consent. Exclusion criteria were: active substance abuse; dementia; severe, active medical disorder. Patients completed a sociodemographic questionnaire and the Hamilton scales for depression (HAM-D)[18] and anxiety (HAM-A).[19] All patients provided written informed consent prior to enrolment, and the ethics committee of S. Andrea Hospital, Sapienza University of Rome, Rome, Italy approved the study.

Statistical analyses

Data were presented as mean ± SD or n patients (%). Bivariate analyses were performed using χ2-test, one-way Fisher exact test, or Student’s t-test for independent samples. After Benjamini and Hochberg correction for multitesting, statistically significant (P < 0.05) variables were selected for multivariate analyses with log-linear models. All statistical analyses were performed using SPSS® version 19.0 (SPSS Inc., Chicago, IL, USA) for Windows®.

Results

The study included 157 patients (67 male and 90 female; mean age 50.15 ± 16.21 years; age range 18–86 years). Of these, 91 (58.0%) had psoriasis, 35 had melanoma (22.3%) and 31 had an allergic dermatological condition (19.7%). For the purposes of the study, patients with melanoma or allergy were combined into a single group (other conditions). Demographic and clinical characteristics of the study population as a whole and patients stratified into groups are shown in Table 1. There were no statistically significant differences between groups in sex distribution, age, education, marital status or employment status. Patients with psoriasis were significantly more likely than those with other conditions to have pathology extending over >80% of the body (P < 0.01) and illness of >8 years’ duration (P < 0.001; Table 1).
Table 1.

Demographic and clinical characteristics of patients with psoriasis or other dermatological conditions (melanoma, allergy) included in the study to examine psychological comorbidity and suicide risk in psoriasis.

CharacteristicAll subjects n = 157Psoriasis group n = 91Other conditions group n = 66Statistical significance[a]
Female90 (57.3)47 (51.6)43 (65.2)NS[b]
Age, years50.15 ± 16.2151.30 ± 14.9148.56 ± 17.76NS
Education > 13 years108 (68.8)59 (64.8)49 (74.2)NS[b]
Married/stable relationship102 (65.0)65 (71.4)37 (56.1)NS[b]
Employment status
 Unemployed19 (12.1)12 (13.2)7 (10.6)
 Employed106 (67.5)61 (67.0)45 (68.2)
 Retired32 (20.4)18 (19.8)14 (21.2)
>80% of body affected30 (19.1)25 (27.5)5 (7.6)P < 0.01[b]
≥2 localizations58 (36.9)40 (44.0)18 (27.3)NS[b]
Illness duration > 8 years76 (48.4)58 (63.7)18 (27.3)P < 0.001[b]
Family history of  dermatological disorders84 (53.5)47 (51.6)37 (56.1)NS[b]
Other chronic comorbidity83 (52.9)47 (51.6)36 (54.5)NS[b]

Data presented as n (%) or mean ± SD unless otherwise indicated.

Vs other conditions group; bone-way Fisher’s exact test; Benjamini and Hochberg correction has beeen used for multitesting correction.

NS, not statistically significant (P ≥ 0.05).

Demographic and clinical characteristics of patients with psoriasis or other dermatological conditions (melanoma, allergy) included in the study to examine psychological comorbidity and suicide risk in psoriasis. Data presented as n (%) or mean ± SD unless otherwise indicated. Vs other conditions group; bone-way Fisher’s exact test; Benjamini and Hochberg correction has beeen used for multitesting correction. NS, not statistically significant (P ≥ 0.05). Data regarding psychiatric comorbidities are shown in Table 2. Patients with psoriasis were significantly more likely than those with other conditions to have experienced major life events in the 12 months before diagnosis (P < 0.05), to have a psychiatric diagnosis (P < 0.01), and to have experienced suicidal ideation in the past (P < 0.01). In addition, patients with psoriasis had significantly more severe current depression than patients with other conditions (P < 0.01).
Table 2.

Psychiatric comorbidities in patients with psoriasis or other dermatological conditions.

ParameterAll subjects n = 157Psoriasis group n = 91Other conditions group n = 66Statistical significance[a]
Life events in 12 months  before symptom onset[c]104 (66.2)67 (73.6)37 (56.1)P < 0.05[b]
 None53 (33.8)24 (26.4)29 (43.9)
 Bereavement/illness in self or others30 (19.1)20 (22.0)10 (15.2)
 Relationship, family or work problems50 (31.8)32 (35.2)18 (27.3)
 Other8 (5.1)6 (6.6)2 (3.0)
 More than one life event16 (10.2)9 (9.9)7 (10.6)
Lifetime psychiatric disorders[c]46 (29.3)35 (38.5)11 (16.7)P < 0.01[b]
 None111 (70.7)56 (61.5)55 (83.3)
 Mood disorders16 (10.2)15 (16.5)1 (1.5)
 Anxiety disorders22 (14.0)14 (15.4)8 (12.1)
Other disorders8 (5.1)6 (6.6)2 (3.0)
 Current suicidal ideation22 (14.0)14 (15.4)8 (12.1)NS[b]
 Past suicidal ideation45 (28.7)34 (37.4)11 (16.7)P < 0.01[b]
 Lifetime suicide attempts6 (3.8)6 (6.6)0 (0.0)NS[b]
HAM-D11.51 ± 6.9312.97 ± 7.369.91 ± 5.99P < 0.01
HAM-D ≥ 1830 (19.1)23 (25.3)7 (10.6)
HAM-A12.47 ± 7.8913.62 ± 9.1910.89 ± 7.51NS
HAM-A ≥ 1837 (23.6)27 (29.7)10 (15.2)

Data presented as n (%) or mean ± SD.

Vs other conditions group; bone-way Fisher’s exact test; Benjamini and Hochberg correction has beeen used for multitesting correction; cLifetime psychiatric disorders and life events in the 12 months before symptom onset have been reported both analitically and as present/absent but have been analyzed only as present/absent.

NS, not statistically significant (P ≥ 0.05); HAM-D, Hamilton scale for depression;[18] HAM-A, Hamilton scale for anxiety.[19]

Psychiatric comorbidities in patients with psoriasis or other dermatological conditions. Data presented as n (%) or mean ± SD. Vs other conditions group; bone-way Fisher’s exact test; Benjamini and Hochberg correction has beeen used for multitesting correction; cLifetime psychiatric disorders and life events in the 12 months before symptom onset have been reported both analitically and as present/absent but have been analyzed only as present/absent. NS, not statistically significant (P ≥ 0.05); HAM-D, Hamilton scale for depression;[18] HAM-A, Hamilton scale for anxiety.[19] Analysis with a log-linear model (fit indices: likelihood ratio χ2 = 14.99; DF = 24; P = 0.92) found that those with psoriasis were significantly more likely than those with other conditions to have illness duration >8 years (risk ratio 3.64; 95% confidence intervals 1.62, 8.18). There was no association between psoriasis and any other variable found to be significant in bivariate analyses.

Discussion

The results of the present study indicate that patients affected by psoriasis are at an increased risk of experiencing lifetime suicidal ideation compared with those with other dermatological conditions, which is in accordance with the findings of others.[14,15,17] As we found in our patient group, patients may experience suicidal ideation before entering the study,[15] suggesting that the course of the illness may be related to a long term psychiatric comorbidity. However, in contrast to others,[14] we did not find a significant increase in current suicidal ideation among patients with psoriasis. Patients with psoriasis in the present study reported more severe depression than those with other conditions. In contrast to others,[15] however, we found no between-group difference in severity of anxiety. Depression is considered a common co-occurring condition in people with psoriasis,[20] and is also an important risk factor for treatment non-adherence. Our findings confirmed this increased number of psychiatric diagnoses in patients with psoriasis, with 38.5% having had a lifetime psychiatric disorder diagnosis compared with 16.7% of patients with other conditions.[12,21,22] Psoriasis is often characterized by the occurrence of a major life event before onset. Our study found that 73.6% of patients with psoriasis reported a negative life event 12 months before the onset of symptoms, which is significantly more than those with other conditions. This result confirmed the previously reported relationship between stressful life events and disease onset, which is more common in psoriasis than in other dermatological conditions.[7] Our findings provide further evidence for the connection between stress and psoriasis, which has been supported by several studies.[3,5,6,22] The long-term course of illness in patients with psoriasis reinforces the effect of this condition on health-related quality-of-life and the risk of psychiatric disorders and suicidal ideation. Our study has several limitations, including the small sample size and cross-sectional study design. In addition, psoriasis naturally has a longer disease course and affects a larger area of the body than other dermatological diseases such as melanoma, which characteristically affects a small area and has a poor 5-year survival rate.[24] In conclusion, the present study confirms that patients with psoriasis have an increased risk of psychiatric comorbidities, suicidal ideation and long-term course of the disease compared with those who have other dermatological conditions. Given the increased risk of suicidal ideation and depressive symptoms, psychiatric and suicide risk assessment is highly recommended, particularly among those with a previous psychiatric diagnosis and history of suicidal ideation. Addressing psychiatric comorbidities is also important to improve patients’ treatment compliance and enhance their health-related quality-of-life.
  24 in total

1.  The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions.

Authors:  M S Al'Abadie; G G Kent; D J Gawkrodger
Journal:  Br J Dermatol       Date:  1994-02       Impact factor: 9.302

2.  Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life.

Authors:  Young Wook Lee; Eun Joo Park; In Ho Kwon; Kwang Ho Kim; Kwang Joong Kim
Journal:  Ann Dermatol       Date:  2010-11-05       Impact factor: 1.444

3.  The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization.

Authors:  S B Perrott; A H Murray; J Lowe; C M Mathieson
Journal:  Physiol Behav       Date:  2000-09-15

4.  The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.

Authors:  Roberto Lande; Elisabetta Botti; Camilla Jandus; Danijel Dojcinovic; Giorgia Fanelli; Curdin Conrad; Georgios Chamilos; Laurence Feldmeyer; Barbara Marinari; Susan Chon; Luis Vence; Valeria Riccieri; Phillippe Guillaume; Alex A Navarini; Pedro Romero; Antonio Costanzo; Enza Piccolella; Michel Gilliet; Loredana Frasca
Journal:  Nat Commun       Date:  2014-12-03       Impact factor: 14.919

Review 5.  Psychiatric morbidity in psoriasis: a review.

Authors:  Paul A J Russo; Ralf Ilchef; Alan J Cooper
Journal:  Australas J Dermatol       Date:  2004-08       Impact factor: 2.875

6.  Prevalence and correlates of suicidal ideation among patients with skin disease.

Authors:  Angelo Picardi; Eva Mazzotti; Paolo Pasquini
Journal:  J Am Acad Dermatol       Date:  2006-01-18       Impact factor: 11.527

7.  Psoriasis and psychiatry: an update.

Authors:  M A Gupta; A K Gupta; H F Haberman
Journal:  Gen Hosp Psychiatry       Date:  1987-05       Impact factor: 3.238

8.  Suicidal ideation in psoriasis.

Authors:  M A Gupta; N J Schork; A K Gupta; S Kirkby; C N Ellis
Journal:  Int J Dermatol       Date:  1993-03       Impact factor: 2.736

9.  Depression and anxiety in psoriatic disease: prevalence and associated factors.

Authors:  Emily McDonough; Renise Ayearst; Lihi Eder; Vinod Chandran; Cheryl F Rosen; Arane Thavaneswaran; Dafna D Gladman
Journal:  J Rheumatol       Date:  2014-04-01       Impact factor: 4.666

10.  Psychosomatic paradigms in psoriasis: Psoriasis, stress and mental health.

Authors:  T S Sathyanarayana Rao; K H Basavaraj; Keya Das
Journal:  Indian J Psychiatry       Date:  2013-10       Impact factor: 1.759

View more
  9 in total

Review 1.  The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities.

Authors:  Ryan Rivera-Oyola; Roselyn Stanger; Graham H Litchman; Quinn Thibodeaux; John Koo; Richard Fried; Gary Goldenberg; George Han; Sylvia Hsu; Leon Kircik; Melissa Knuckles; Andrea Murina; Jeffrey Weinberg; Jashin J Wu; Mark Lebwohl
Journal:  J Clin Aesthet Dermatol       Date:  2020-12-01

Review 2.  The Psoriasis Decision Tree.

Authors:  George Monks; Ryan Rivera-Oyola; Mark Lebwohl
Journal:  J Clin Aesthet Dermatol       Date:  2021-04-01

3.  Psychological Distress, Alexithymia and Alcohol Misuse in Patients with Psoriasis: A Cross-Sectional Study.

Authors:  Ourania Founta; Karoline Adamzik; Anne-Marie Tobin; Brian Kirby; David Hevey
Journal:  J Clin Psychol Med Settings       Date:  2019-06

4.  Untargeted serum metabonomics study of psoriasis vulgaris based on ultra-performance liquid chromatography coupled to mass spectrometry.

Authors:  Li Li; Lu Chuan-Jian; Han Ling; Deng Jing-Wen; He Ze-Hui; Yan Yu-Hong; Zhang Zhong-Zhao
Journal:  Oncotarget       Date:  2017-10-06

Review 5.  Affibody molecules as engineered protein drugs.

Authors:  Fredrik Y Frejd; Kyu-Tae Kim
Journal:  Exp Mol Med       Date:  2017-03-24       Impact factor: 8.718

6.  Psychopathology and Alexithymia in Patients with Moderate-to-Severe Psoriasis: Development of a Novel Index with Prognostic Value.

Authors:  Sofia Tsiori; Natalia Rompoti; Konstantinos Kontoangelos; Christos Papageorgiou; Charalabos Papageorgiou; Alexander Stratigos; Dimitrios Rigopoulos
Journal:  Int J Environ Res Public Health       Date:  2022-03-29       Impact factor: 3.390

7.  Antipsychotic-associated psoriatic rash - a case report.

Authors:  Camelia-Eugenia Bujor; Torkel Vang; Jimmi Nielsen; Ole Schjerning
Journal:  BMC Psychiatry       Date:  2017-07-04       Impact factor: 3.630

Review 8.  The Pathophysiological Mechanisms and the Quest for Biomarkers in Psoriasis, a Stress-Related Skin Disease.

Authors:  Mircea Tampa; Maria-Isabela Sarbu; Madalina-Irina Mitran; Cristina-Iulia Mitran; Clara Matei; Simona-Roxana Georgescu
Journal:  Dis Markers       Date:  2018-01-28       Impact factor: 3.434

9.  Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy.

Authors:  Shinichi Imafuku; Min Zheng; Yayoi Tada; Xibao Zhang; Colin Theng; Suganthi Thevarajah; Yi Zhao; Hae Jun Song
Journal:  J Dermatol       Date:  2018-05-09       Impact factor: 4.005

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.